Nizatidine
-
Nizatidine
structure -
-
CAS No:
76963-41-2
-
Formula:
C12H21N5O2S2
-
Chemical Name:
Nizatidine
-
Synonyms:
1,1-Ethenediamine,N′-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N-methyl-2-nitro-;1,1-Ethenediamine,N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N′-methyl-2-nitro-;N′-[2-[[[2-[(Dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N-methyl-2-nitro-1,1-ethenediamine;Nizatidine;LY 139037;Axid;Acinon;Tazac;Bonacid;Distaxid;Calmaxid;ZL 101;Nizax;Naxidine;Nizaxid;Cronizat;Zanizal;Gastrax
- Categories:
-
CAS No:
Description
Nizatidine is a histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion.Target: Histamine H2 ReceptorNizatidine, a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion, with IC50 of 0.9 nM. Nizatidine exhibits maximal inhibition of gastric acid in rats within the first hour of drug administration, with EC50 of 1.383 μmol/kg [1]. Nizatidine also reversibly inhibits acetylcholinesterase (AChE), with IC50 of 6.7 μM, and
Nizatidine is a Histamine-2 Receptor Antagonist. The mechanism of action of nizatidine is as a Histamine H2 Receptor Antagonist.|Nizatidine is a competitive and reversible histamine H2-receptor antagonist with antacid activity. Nizatidine inhibits the histamine H2-receptors located on the basolateral membrane of the gastric parietal cell, thereby reducing basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli.|A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Characteristics
140
1.6
white to off-white crystalline powder
1.2±0.1 g/cm3
130-132 °C
243.0±28.7 °C
1.592
H2O: 10-33mg/mL
-20°C Freezer
LD50 in mice, rats (mg/kg): 265, >300 i.v.; 1685, 1680 orally (Pioch)
Drug Information
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)|Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Axid
Nizatidine Use and Manufacturing
N-METHYL-L-METHYLTHIO-2-NITROETHYLENEAMINE (NMSM, 610 g; 4.12 mol) is mixed with water (1500 ml), and the mixture is cool to 20-25 C. 4- (2-Aminoethyl) DIIOMETHYL-2-DIMETHYLAMINOMETHYLTHIAZOLE (1000 g; 4.32 mol) dissolved in water (1500 ML) is added into this suspension at 20-25 C. The reaction mixture is warmed to 30-35° C and continued the reaction for 8 h. The progress of the reaction is monitored by qualitative HPLC analysis. The reaction mixture is extracted with toluene (2 x 1000 ml), and the aqueous layer is treated with activated carbon (50 g) at 55-60 C for 30 min. Activated carbon is removed by filtration through HYFLO bed and the aqueous filtrate is extracted with chloroform (4 x 1000 I THE CHLOROFORM extract is concentrated under reduced pressure at less than 50 C ; ethyl acetate (3000 ML) is added into the concentrate and reconcentrated. Acetone (300 ml), ethyl acetate (300 ML) is added into the concentrate and cooled to 0-5 C to crystallize the product. The product is filtered, washed with precooled ethyl acetate (250 ml), and dried to obtain pure Nizatidine 1160 g. Yield = 81.0percent ; HPLC purity ~ 99.3percent.Weigh 102g of 2- (dimethylaminomethyl) -4- (2-aminoethylthiomethyl) thiazole64.3 g of N-methyl-1-methylthio-2-nitroethylene amine, mixing, Add 306mL of water, At 30 ° C until the reaction of the starting material is complete, Then add 10g activated carbon bleaching, Suction filtration, Finally, add 400mL of anhydrous ethanol for recrystallization, The recrystallization process is:The material obtained by suction filtration was added to absolute ethanol, Begin to heat up to 70 , Then heat to solid all dissolved, Then slowly cooled to 0-5 , Insulation 6h, Finally centrifugedNizatidineThe yield of this process is 80.6percentPurity 99.7percent.
The value of nizatidine in the treatment of peptic ulcer disease is comparable to that of ranitidine and cimetidine. Dosing once or twice a day usually cures duodenal ulcer within 8 weeks; a single daily dose prevents recurrence. The effect of nizatidine in the treatment of gastric ulcers is similar to that of other H2 receptor blockers, but little information is available. For reflux esophagitis, Zollinger-Ellison syndrome, and other peptic ulcer diseases, its effect is expected to be equal to that of ranitidine, but it needs clinical research to confirm.
Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Computed Properties
Molecular Weight:331.5
XLogP3:1.6
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:9
Exact Mass:331.11366728
Monoisotopic Mass:331.11366728
Topological Polar Surface Area:140
Heavy Atom Count:21
Complexity:349
Undefined Bond Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Drug Function and Efficacy
Nizatidine is a histamine H2 receptor antagonist, which competitively binds to histamine H2 receptors and reversibly inhibits receptor function, especially H2 receptors on gastric parietal cells that secrete gastric acid, blocking gastric acid formation and reducing basal gastric acid. It can also inhibit gastric acid secretion caused by food and chemical stimulation. Oral administration of 300 mg of this product can significantly inhibit gastric acid secretion at night (about 12 hours), with an inhibition rate of 90%; it significantly inhibits gastric acid secretion caused by food, caffeine, aminopyrazole and pentagastrin stimulation, with inhibition rates of 97%, 96%, 99% and 67% respectively. Oral administration of 75-300 mg of this product does not affect the activity of pepsin in gastric secretions, but the total amount of pepsin secretion decreases with the decrease of gastric secretion.
Registered Holders
-
Suzhou Wanqing Pharmaceutical Co., Ltd.
Active
China
-
Sichuan Mol Biopharma Co., Ltd.
Active
China
-
Hainan Shating NING Pharmaceutical Co., Ltd.
Active
China
Recommended Suppliers of Nizatidine
-
CN
5 YRS
Business licensed Certified factoryManufactory Supplier of fine chemicals,pharmaceutical materials -
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
CN
5 YRS
Business licensedTrader Supplier of PVC resin,pvc paste resin,melamineInquiryCAS No.: 76963-41-2Grade: Industrial GradeContent: 99%
Learn More Other Chemicals
-
Des(N'-Methyl-2-nitro-1,1-ethenediaMino) N'-Methylureido Nizatidine
82586-81-0
-
Sofalcone
64506-49-6
-
Dolasetron mesylate
115956-13-3
-
Lorcaserin hydrochloride Formula
846589-98-8
-
(-)-Omeprazole Formula
119141-88-7
-
Alvimopan Formula
156053-89-3
-
Alibendol Structure
26750-81-2
-
Potassium glycyrrhizinate Structure
68039-19-0
-
What is (-)-Alkannin
517-88-4
-
What is Orazamide
2574-78-9